Recce Pharmaceuticals Bolsters Clinical Trial Funds
Company Announcements

Recce Pharmaceuticals Bolsters Clinical Trial Funds

Recce Pharmaceuticals Ltd. (AU:RCE) has released an update.

Recce Pharmaceuticals Ltd. has successfully closed its Share Purchase Plan, raising A$4.4 million from shareholders, contributing to a total fundraise of A$12.4 million in conjunction with an earlier institutional placement. These funds will support the advancement of clinical trials and development activities for their Synthetic Anti-Infective products, boosting their cash position to A$19.8 million. The company’s shareholders were fully supportive, with the new shares expected to be issued and quoted on the ASX shortly after the announcement.

For further insights into AU:RCE stock, check out TipRanks’ Stock Analysis page.

Related Articles
TipRanks Australian Auto-Generated NewsdeskRecce Pharmaceuticals Boosted by $6.75M R&D Rebate
TipRanks Australian Auto-Generated NewsdeskRecce Pharmaceuticals Issues New Options for Growth
TipRanks Australian Auto-Generated NewsdeskRecce Pharmaceuticals Advances Phase 3 Trial in Indonesia
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App